Studies have suggested that metformin suppresses inflammation in diabetes and intestinal inflammation by inhibiting the activity of NF-κB via AMPK-independent and AMPK-dependent processes [52–55]. This evidence concerns the gene NFKB1 and diabetes mellitus.